Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET
Company Participants
Bryan Giraudo – COO & CFO
Faheem Hasnain – Co-Founder, CEO, President & Chairman
Richard Aranda – Chief Medical Officer
Caryn Peterson – EVP, Regulatory Affairs
Bob Smith – Chief Commercial Officer
Conference Call Participants
Joseph Schwartz – SVB Leerink
Andreas Argyrides – Oppenheimer
Yasmeen Rahimi – Piper Sandler & Co.
Paul Choi – Goldman Sachs
Olivia Brayer – Cantor
Patrick Trucchio – HC Wainwright
Laura Chico – Wedbush
Operator
Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 2025 Earnings Call.
I will now turn the program over to Bryan Giraudo, Chief Financial Officer and Chief Operating Officer.
Bryan Giraudo
Thank you, operator, and thank you all for joining us this afternoon. I am joined on today’s call by Faheem Hasnain, Gossamer’s Founder, Chairman, and Chief Executive Officer; Dr. Richard Aranda, Chief Medical Officer, Caryn Peterson, Executive Vice President, Regulatory Affairs, and Bob Smith, Chief Commercial Officer.
Earlier this afternoon, Gossamer Bio issued a press release announcing its first quarter 2025 financial results and provided a corporate update.
Please note that certain information discussed on the call today is covered under the Safe provision of the Private Securities Litigation Reform Act. We caution listeners that during the call, Gossamer management will be making forward-looking statements. Actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company’s business.
These forward-looking statements are qualified by statements contained in Gossamer’s news releases, SEC filings, including the annual report on Form 10-K and subsequent filings. This conference call also contains time-sensitive information that may be accurate only for a limited period of time. Gossamer BIO undertakes no obligation to revise or update any forward-looking statements
#Gossamer #Bio #GOSS #Earnings #Conference #Call #Transcript